ALBUMIN-BOUND PACLITAXEL (ABRAXANE) + CARBOPLATIN
NCCN GUIDELINES® CATEGORY 1 RECOMMENDED OPTION

Albumin-bound paclitaxel (ABRAXANE®) + carboplatin is a treatment option included in the NCCN Guidelines with a Category 1 recommendation for the first-line treatment of metastatic NSCLC squamous cell carcinoma and nonsquamous cell carcinoma (PS 0-1)b - image Albumin-bound paclitaxel (ABRAXANE®) + carboplatin is a treatment option included in the NCCN Guidelines with a Category 1 recommendation for the first-line treatment of metastatic NSCLC squamous cell carcinoma and nonsquamous cell carcinoma (PS 0-1)b - image
  • a For additional considerations and treatment options, see NCCN.org.
  • b EGFR, ALK, ROS-1, BRAF, and PD-L1 negative or unknown.
  • NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • PS=performance status.
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL